Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2

Objective To assess changes in international mortality rates and laboratory recovery rates during hospitalisation for patients hospitalised with SARS-CoV-2 between the first wave (1 March to 30 June 2020) and the second wave (1 July 2020 to 31 January 2021) of the COVID-19 pandemic. Design, setting and participants This is a retrospective cohort study of 83 178 hospitalised patients admitted between 7 days before or 14 days after PCR-confirmed SARS-CoV-2 infection within the Consortium for Clinical Characterization of COVID-19 by Electronic Health Record, an international multihealthcare system collaborative of 288 hospitals in the USA and Europe. The laboratory recovery rates and mortality rates over time were compared between the two waves of the pandemic. Primary and secondary outcome measures The primary outcome was all-cause mortality rate within 28 days after hospitalisation stratified by predicted low, medium and high mortality risk at baseline. The secondary outcome was the average rate of change in laboratory values during the first week of hospitalisation. Results Baseline Charlson Comorbidity Index and laboratory values at admission were not significantly different between the first and second waves. The improvement in laboratory values over time was faster in the second wave compared with the first. The average C reactive protein rate of change was –4.72 mg/dL vs –4.14 mg/dL per day (p=0.05). The mortality rates within each risk category significantly decreased over time, with the most substantial decrease in the high-risk group (42.3% in March–April 2020 vs 30.8% in November 2020 to January 2021, p<0.001) and a moderate decrease in the intermediate-risk group (21.5% in March–April 2020 vs 14.3% in November 2020 to January 2021, p<0.001). Conclusions Admission profiles of patients hospitalised with SARS-CoV-2 infection did not differ greatly between the first and second waves of the pandemic, but there were notable differences in laboratory improvement rates during hospitalisation. Mortality risks among patients with similar risk profiles decreased over the course of the pandemic. The improvement in laboratory values and mortality risk was consistent across multiple countries.

[1]  Jeffrey G. Klann,et al.  Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National EHR Research Consortium Study , 2022, medRxiv.

[2]  B. Luft,et al.  Clinical risk factors for mortality in an analysis of 1375 patients admitted for COVID treatment , 2021, Scientific Reports.

[3]  Jason W. Moore,et al.  Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 , 2021, Scientific Reports.

[4]  T. Zewotir,et al.  Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients , 2021, BMC Infectious Diseases.

[5]  Seong-Ho Choi,et al.  Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study , 2021, PloS one.

[6]  C. Fuentes-Orozco,et al.  Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study , 2021, BMJ Open.

[7]  Jeffrey G. Klann,et al.  International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint) , 2021 .

[8]  M. Kivipelto,et al.  Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study , 2021, Journal of the American Medical Directors Association.

[9]  Xu-guang Guo,et al.  Liver injury in COVID-19: clinical features and treatment management , 2021, Virology Journal.

[10]  Jordan J. Clark,et al.  Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK , 2021, The Lancet Respiratory Medicine.

[11]  L. Finelli,et al.  Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020 , 2021, JAMA network open.

[12]  S. Zeger,et al.  Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19 , 2021, JAMA network open.

[13]  S. Pini,et al.  Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study , 2021, Respiratory Medicine.

[14]  J. Hochman,et al.  C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.

[15]  Shaorui Shi,et al.  Clinical and laboratory characteristics of severe and non‐severe patients with COVID‐19: A retrospective cohort study in China , 2021, Journal of clinical laboratory analysis.

[16]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[17]  D. Asch,et al.  Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic , 2020, JAMA internal medicine.

[18]  C. Tebé,et al.  A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.

[19]  J. Rigdon,et al.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.

[20]  Samuel M. Brown,et al.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[21]  H. Ohtsu,et al.  First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics , 2020, Journal of Infection.

[22]  S. Vollmer,et al.  Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020* , 2020, Critical care medicine.

[23]  R. Anderson,et al.  Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[24]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[25]  Arthur S Slutsky,et al.  Evaluation of PEEP and prone positioning in early COVID-19 ARDS , 2020, EClinicalMedicine.

[26]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[27]  T. Ortel,et al.  ISTH DIC subcommittee communication on anticoagulation in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[28]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[29]  Jeffrey G. Klann,et al.  International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium , 2020, npj Digital Medicine.

[30]  Leora I. Horwitz,et al.  Trends in Covid-19 risk-adjusted mortality rates in a single health system , 2020, medRxiv.

[31]  R. Schwartz,et al.  Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. , 2020, JAMA.

[32]  A. Saqi,et al.  Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data , 2020, Modern Pathology.

[33]  M. Shankar-Hari,et al.  Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland , 2020, American journal of respiratory and critical care medicine.

[34]  S. Heydari,et al.  Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis , 2020, European Journal of Medical Research.

[35]  Jer Ping Ooi,et al.  Risk factors for mortality among COVID-19 patients , 2020, Diabetes Research and Clinical Practice.

[36]  Tingmei Wang,et al.  Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests , 2020, Travel Medicine and Infectious Disease.

[37]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[38]  Bachti Alisjahbana,et al.  C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis , 2020, Therapeutic advances in respiratory disease.

[39]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[40]  M. Thomeer,et al.  Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? , 2020, European Respiratory Journal.

[41]  F. S. Cardoso,et al.  Liver injury in critically ill patients with COVID-19: a case series , 2020, Critical Care.

[42]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[43]  D. Goyal,et al.  Early intervention likely improves mortality in COVID-19 infection. , 2020, Clinical medicine.

[44]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[45]  S. Susen,et al.  Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. , 2020, Circulation.

[46]  Brett K. Beaulieu-Jones,et al.  International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium , 2020, npj Digital Medicine.

[47]  Lei Liu,et al.  COVID-19: Abnormal liver function tests , 2020, Journal of Hepatology.

[48]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[49]  L. Tang,et al.  Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis , 2020, Journal of Thrombosis and Thrombolysis.

[50]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[51]  Yi Yang,et al.  Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province , 2020, Annals of Intensive Care.

[52]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[53]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[54]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[55]  Jamison D. Fargo,et al.  Regional Variations in Documentation of Sexual Trauma Concepts in Electronic Medical Records in the United States Veterans Health Administration , 2019, AMIA.

[56]  T. Kurth,et al.  The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients , 2015, BMJ Open.

[57]  G. Van den Berghe,et al.  Cholestatic liver (dys)function during sepsis and other critical illnesses , 2015, Intensive Care Medicine.

[58]  Philip Hall,et al.  What is the Real Function of the Liver ‘Function’ Tests? , 2012, The Ulster medical journal.

[59]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[60]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[61]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[62]  Tianxi Cai,et al.  Evaluating Prediction Rules for t-Year Survivors With Censored Regression Models , 2007 .

[63]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[64]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[65]  R. Tibshirani The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[66]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[67]  J. Hoofnagle,et al.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. , 1988, Gastroenterology.

[68]  M. Stone Cross‐Validatory Choice and Assessment of Statistical Predictions , 1976 .